Tags

Type your tag names separated by a space and hit enter

Effect of oral valaciclovir on herpetic keratitis.
Cornea. 2006 Dec; 25(10 Suppl 1):S64-7.C

Abstract

PURPOSE

To examine the efficacy of valaciclovir (VACV) oral formulation as an alternative to topical treatments in a case of herpetic keratitis.

METHODS

The patient was a 61-year-old man who presented with dendritic keratitis in his left eye. After recognizing his difficulty in using eye ointment, we prescribed oral VACV 500 mg tablets twice daily for 7 days. We also describe our experiments with orally administered VACV in a mouse model of this disease. In this study, 143 Balb/c mice were inoculated with herpes simplex virus type 1 (HSV)-1 in each eye and treated with oral VACV 50 or 100 mg/kg twice daily, oral acyclovir (ACV) 50 mg/kg 5 times/d, 3% ACV eye ointment (ACV-O) 5 times/d, 3% ACV eye drops 5 times/d, or control for 5 days.

RESULTS

After 7 days, the patient's lesion was observed healed. Corrected left visual acuity was also improved, and HSV DNA was below detectable level. In the mouse study, slit-lamp examination on days 3, 4, 5, and 7 revealed that all 5 ACV and VACV treatment groups were significantly more effective in improving symptoms of herpetic epithelial keratitis versus control (P < 0.05). Moreover, VACV 100 mg/kg was superior to other treatments. Viral titers in mouse eyeball and trigeminal ganglia were lowest in the VACV 100 mg/kg group versus other treatment groups.

CONCLUSION

Our case example suggests that when frequent application, blurred vision, and foreign body sensation after ACV-O application cause difficulty for patients to follow treatment, oral VACV might be an effective and safe option for patients with herpetic keratitis.

Authors+Show Affiliations

Department of Ophthalmology, Kinki University School of Medicine, 377-2 Ohno Higashi, Osaka Sayama City, Osaka, Japan. higaki@ganka.med.kindai.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17001196

Citation

Higaki, Shiro, et al. "Effect of Oral Valaciclovir On Herpetic Keratitis." Cornea, vol. 25, no. 10 Suppl 1, 2006, pp. S64-7.
Higaki S, Itahashi M, Deai T, et al. Effect of oral valaciclovir on herpetic keratitis. Cornea. 2006;25(10 Suppl 1):S64-7.
Higaki, S., Itahashi, M., Deai, T., Fukuda, M., & Shimomura, Y. (2006). Effect of oral valaciclovir on herpetic keratitis. Cornea, 25(10 Suppl 1), S64-7.
Higaki S, et al. Effect of Oral Valaciclovir On Herpetic Keratitis. Cornea. 2006;25(10 Suppl 1):S64-7. PubMed PMID: 17001196.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of oral valaciclovir on herpetic keratitis. AU - Higaki,Shiro, AU - Itahashi,Motoki, AU - Deai,Tatsunori, AU - Fukuda,Masahiko, AU - Shimomura,Yoshikazu, PY - 2006/9/27/pubmed PY - 2007/4/27/medline PY - 2006/9/27/entrez SP - S64 EP - 7 JF - Cornea JO - Cornea VL - 25 IS - 10 Suppl 1 N2 - PURPOSE: To examine the efficacy of valaciclovir (VACV) oral formulation as an alternative to topical treatments in a case of herpetic keratitis. METHODS: The patient was a 61-year-old man who presented with dendritic keratitis in his left eye. After recognizing his difficulty in using eye ointment, we prescribed oral VACV 500 mg tablets twice daily for 7 days. We also describe our experiments with orally administered VACV in a mouse model of this disease. In this study, 143 Balb/c mice were inoculated with herpes simplex virus type 1 (HSV)-1 in each eye and treated with oral VACV 50 or 100 mg/kg twice daily, oral acyclovir (ACV) 50 mg/kg 5 times/d, 3% ACV eye ointment (ACV-O) 5 times/d, 3% ACV eye drops 5 times/d, or control for 5 days. RESULTS: After 7 days, the patient's lesion was observed healed. Corrected left visual acuity was also improved, and HSV DNA was below detectable level. In the mouse study, slit-lamp examination on days 3, 4, 5, and 7 revealed that all 5 ACV and VACV treatment groups were significantly more effective in improving symptoms of herpetic epithelial keratitis versus control (P < 0.05). Moreover, VACV 100 mg/kg was superior to other treatments. Viral titers in mouse eyeball and trigeminal ganglia were lowest in the VACV 100 mg/kg group versus other treatment groups. CONCLUSION: Our case example suggests that when frequent application, blurred vision, and foreign body sensation after ACV-O application cause difficulty for patients to follow treatment, oral VACV might be an effective and safe option for patients with herpetic keratitis. SN - 0277-3740 UR - https://www.unboundmedicine.com/medline/citation/17001196/Effect_of_oral_valaciclovir_on_herpetic_keratitis_ L2 - http://dx.doi.org/10.1097/01.ico.0000247216.08886.9d DB - PRIME DP - Unbound Medicine ER -